Dual checkpoint blockade improves PFS as first-line treatment of advanced melanoma

Source: Healio, May 2021

The addition of relatlimab to nivolumab conferred a significant PFS benefit among treatment-naive patients with advanced melanoma, according to results of the phase 2/phase 3 RELATIVITY-047 study presented at the virtual ASCO Annual Meeting.

The data showed the combination of relatlimab (BMS-986016, Bristol Myers Squibb), a human IgG4 lymphocyte-activation gene 3 (LAG-3)-blocking antibody, plus the anti-PD-1 agent nivolumab (Opdivo, Bristol Myers Squibb), was well-tolerated and had a manageable safety profile.

READ THE ORIGINAL FULL ARTICLE